Search for: "Ely Lilly"
Results 341 - 360
of 2,173
Sort by Relevance
|
Sort by Date
20 Jun 2018, 4:12 am
C-322/10 – Medeva, C-518/10 – Yeda, C-630/10 – University of Queensland, C-6/11 – Daiichi Sankyo, C-493/12 – Eli Lilly, and C-443/12 – Actavis/Sanofi) and came to the conclusion that the requirements of Article 3(a) of the EU SPC-Regulation No 469/2009, i.e. whether the product of an SPC is protected by the basic patent, are unclear and, therefore, there was no reason to move away from the infringement test. [read post]
4 Jun 2018, 3:02 am
Image credits: Sleepwalking - GIPHYAmsterdam - Shovy Rahman PREVIOUSLY ON NEVER TOO LATENever Too Late 194 [weeks ending 13th and 20th May] Important amendments under Mexican law regarding patents, utility models and industrial designs | Decoding the Scope of Patent Protection: Singapore after Eli Lilly v. [read post]
1 Jun 2018, 12:13 pm
Eli Lilly & Co. v. [read post]
31 May 2018, 6:25 am
Pharmaceutical maker “Eli Lilly, referring to two popular antidepressants, said in a statement the company ‘remains committed to Prozac [fluoxetine] and Cymbalta [duloxetine] and their safety and benefits, which have been repeatedly affirmed by the US Food and Drug Administration. [read post]
28 May 2018, 7:53 am
Eli Lilly pemetrexed battles here, here and here. [read post]
21 May 2018, 7:22 pm
Eli Lilly & Co., 598 F.3d 1336 (Fed. [read post]
18 May 2018, 5:25 am
Eli Lilly& Co., 598 F.3d 1336, 1351 (Fed. [read post]
17 May 2018, 1:36 pm
Having presided over major decisions impacting both on IP law and practice, not the least Actavis v Eli Lilly, Baron Neuberger will be sharing his insights and reflections on “IP in the UK and Europe – a view from the top”. [read post]
14 May 2018, 12:30 pm
Birss would not be drawn on his views of the Supreme Court's decision in Eli Lilly v Actavis (see the IPKat here - the 109 comments on the post is a good indication of how controversial this decision has been). [read post]
10 May 2018, 11:12 pm
The UK Supreme Court's decision in Eli Lilly v. [read post]
6 Apr 2018, 8:03 am
The Court of Appeal heard arguments regarding whether, if they had accepted Kymab's construction of "in situ replacement", they could nevertheless have found infringement on the basis of Actavis v Eli Lilly (Eli Lilly v Actavis UK [2017] UKSC 48, IPKat post). [read post]
16 Mar 2018, 12:00 am
The SEC agreed with Eli Lilly’s reasoning, and concluded Eli Lilly could omit the proposal under Rule 14a-8(i)(10). [read post]
14 Mar 2018, 8:41 am
Eli Lilly & Co., 598 F.3d 1336 (Fed. [read post]
9 Mar 2018, 1:00 am
Recent cases such as Trunki and Actavis v Eli Lilly in the Supreme Court and the CJEU ruling in Specsavers have drawn into focus the relationship between the representation contained on the patent, trade mark and design registers and the scope of protection conferred by those registrations. [read post]
8 Mar 2018, 6:48 am
Following Actavis vs Eli Lilly, is the UK becoming more author-centric? [read post]
3 Mar 2018, 2:35 am
Jane Lambert Patents Court (Mr Justice Arnold): Generics (UK) Ltd (t/a Mylan) and another v Yeda Research And Development Company Ltd [2017] EWHC 2629 (Pat) (26 Oct 2017) On Wednesday, 28 Feb 2018 I gave a talk to the C5 Pharma and Patent Litigation Conference at the Radisson Blu Hotel in Amsterdam. [read post]
1 Mar 2018, 2:35 pm
For instance, earlier this year Eli Lilly & Co. reached a settlement over federal product liability lawsuits pending for damage caused by its testosterone drug Axiron. [read post]
1 Mar 2018, 2:35 pm
For instance, earlier this year Eli Lilly & Co. reached a settlement over federal product liability lawsuits pending for damage caused by its testosterone drug Axiron. [read post]
23 Feb 2018, 4:15 am
Eli Lilly and Co. v. [read post]
23 Feb 2018, 4:15 am
Eli Lilly and Co. v. [read post]
